Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston
3
×
boston blog main
boston top stories
drugs
3
×
life sciences
national blog main
alnylam pharmaceuticals
aminolevulinic acid
clinical trials
fda
givosiran
paul matteis
rna interference
accelerated approval
acute hepatic porphyria
acute hepatic porphyrias
akin akinc
biotech
crispr
cystic fibrosis
cystic fibrosis foundation
gilead sciences
hepatitis c
incivek
jeff leiden
kayldeco
matt emmens
messenger rna therapeutics
national top stories
onpattro
orkambi
patisiran
people
sickle cell disease
stifel
stifel financial
symdeko
vertex pharmaceuticals
What
pharmaceuticals
3
×
alnylam
drug
interference
medicine
rna
rnai
second
seek
speedy
ago
approval
cf
cleared
crisis
cystic
data
developer
far
fda
fibrosis
force
helped
indicated
jeff
leiden
market
medicines
nasdaq
new
nod
ok
profitable
quick
roles
shaped
steer
step
switch
vertex
Language
unknown
Current search:
drugs
×
boston
×
pharmaceuticals
×
@xconomy.com
4 years ago
Jeff Leiden, Who Shaped Vertex Into a CF Force, to Switch Roles
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug